Outstanding publication of our partner Renalytix

Outstanding publication of our partner Renalytix about kidneyintelX.dkd: a prognostic test for the assessment of diabetic kidney disease progression

The PRIME-CKD consortium is proud to share with you a new publication by our partner Renalytix.

This study describes the development and validation of an updated version of KidneyIntelX (kidneyintelX.dkd) to stratify patients for risk of progression of diabetic kidney disease (DKD) stages 1 to 3, simplifying the test for clinical adoption. They used two independent cohorts and a clinical trial population and validated an updated KidneyIntelX test (named kidneyintelX.dkd), which significantly enhanced risk stratification in patients with DKD for PDKF, independently from known risk factors for progression. The data was used to support an application to the US Food and Drug Administration regulatory pathway.

You can find more information about this excellent article here.